UNIVERSIDAD DE PUERTO RICO, RECINTO DE CIENCIAS MÉDICAS
UNIVERSITY OF PUERTO RICO, MEDICAL SCIENCES CAMPUS

OFICINA DEL RECTOR
OFFICE OF THE CHANCELLOR

COMITE DE DERECHOS HUMANOS (IRB)
INSTITUTIONAL REVIEW BOARD

Date: December 20, 2016

Protocol Number: A7080216

Principal Investigator: Edna Acosta Pérez

Department / Division: School of Public Health

Sponsor: CDC

Title: ***Monitoring and Evaluation for the Zika Contraception Access Network (Z-CAN): Phase I***
Evaluación y monitor de la Red de Acceso a Anticonceptivos y el Zika (Z-CAN): Fase I

Thank you for your response to requests from a prior **full board review** of your application. This is to confirm that your application is now fully approved. In compliance with federal regulations, the approval for this study is valid through: **December 20, 2016** to **December 20, 2017**.

This action involves:
- ☒ New

The following documents were reviewed under this submission:
- ☒ Protocol
- ☒ Informed Consent Document
  Spanish Version
- ☒ Survey Instrument
- ☒ Advertisement
- ☒ Human Subject Certified
- ☒ Curriculum Vitae
- ☒ HIPAA Certified
- ☒ Authorization Letter
- ☒ HIPAA Identifiers

This project includes children or adolescents IRB determined the risk/ benefit category as:
- ☒ 45 CFR §46.404 Research not involving greater than minimal risk.

For additional information please contact Human Research Subjects Protection Office at 787-758-2525 exts. 2510 to 2515; e-mail opphi.rcm@upr.edu.

Cordially,

Luz A. Muñiz, EdD
Chairperson IRB 3

bcg

1. Research must be conducted according to the proposal that was approved by the IRB.
2. Changes to the protocol or its related consent document must be approved by the IRB prior to implementation.
3. All serious or unexpected adverse events/drug reactions should be reported.
4. Each subject should receive a copy of the consent document, if appropriate.
5. Records must be retained for at least three years.
6. Any future correspondence should include the IRB identification number provided and the study title.